Rapid Urine Test Detects Early Kidney Injury
|
By LabMedica International staff writers Posted on 05 May 2014 |
|
Image: The NephroCheck Test cartridge and Astute140 Meter (Photo courtesy of Astute Medical).
A new test utilizes fluorescence immunoassay technology to detect and measure two biomarkers that reflect the risk of developing acute kidney injury (AKI).
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
The NephroCheck Test measures tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP-7) in human urine. Both are involved in G1 cell cycle arrest during the very early phases of cellular stress, and are robust measures of risk for AKI manifesting within the following 12-24 hours. TIMP-2 is an inhibitor of the matrix metalloproteinases (MMPs) that directly suppress the proliferation of endothelial cells. IGFBP-7 is involved in the regulation of tissue availability of insulin and IGFs, and stimulates cell adhesion implicated in epithelial cell-cycle arrest.
For the test, a sample of a patient’s urine is mixed with reagents onto a single-use cartridge inserted into the proprietary Astute140 Meter. The meter employs a sandwich immunoassay technique along with fluorescence detection technology to quantitatively measure the biomarker concentrations, combining them into a single numerical test result. Multiple levels of controls (internal, external, and electronic) are used to ensure reliable and accurate results in about 20 minutes. The NephroCheck Test and Astute140 Meter are products of Astute Medical (San Diego, CA, USA), and have received the European Community CE marking of approval.
“We believe the NephroCheck Test will be able to help physicians address one of the most costly, deadly, and confounding conditions affecting intensive care hospital patients,” said Chris Hibberd, CEO of Astute Medical. “With increasing constraints on healthcare spending, innovative tools such as the NephroCheck Test will be essential to ensuring that the right resources get to the right patients at the right time.”
AKI is a significant global health hazard that strikes up to seven percent of hospitalized patients. AKI often occurs in patients that are already suffering from myriad issues such as sepsis, trauma, surgery, or being treated with nephrotoxic drugs, further complicating diagnosis, while also increasing mortality rates.
Related Links:
Astute Medical
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Laboratory Software
ArtelWare
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Molecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read more
Hematology
view channel
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read more
Immunology
view channel
Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Microbiology
view channel
AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read more
Pathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read more
Technology
view channel
Aptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read more
Industry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
